ArticleJournal of translational medicine2008
Anti-angiogenic effect of high doses of ascorbic acid.
Article in Journal of translational medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01125449 (Phase 2 Study of High Dose Ascorbic Acid in Solid Tumor Disease), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of High Dose Ascorbic Acid in Solid Tumor Disease
Who cites it
29 citing papers in PubMed.
- Beyond redox: vitamin C in signaling, epigenetic regulation and protein modification-relevance to cancer therapy.Clinical epigenetics · 2026Review
- The protective role of vitamin C in diabetic retinopathy and TPT1 as a potential therapeutic target.Nutrition & metabolism · 2026Article
- Potentiation of Tumor Hallmarks by the Loss of GULO, a Vitamin C Biosynthesis Gene in Humans.Current molecular medicine · 2025Review
- Dysregulation of amino acids balance as potential serum-metabolite biomarkers for diagnosis and prognosis of diabetic retinopathy: a metabolomics study.Journal of diabetes and metabolic disorders · 2024Article
- Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients.Antioxidants (Basel, Switzerland) · 2024Article
- An irreversible paper-based profluorescent nitroxide probe for the selective detection of ascorbic acid.RSC advances · 2023Article
- The Pivotal Immunoregulatory Functions of Microglia and Macrophages in Glioma Pathogenesis and Therapy.Journal of oncology · 2022Review
- Coculture of Endothelial and Stromal Cells to Promote Concurrent Osteogenesis and Vasculogenesis.Tissue engineering. Part A · 2021Article
- Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer.Biomolecules · 2021Review
- Micronutrient Food Supplements in Patients with Gastro-Intestinal and Hepatic Cancers.International journal of molecular sciences · 2021Review
- Coupling Osteogenesis and Vasculogenesis in Engineered Orthopedic Tissues.Tissue engineering. Part B, Reviews · 2021Review
- Antioxidant, Anti-Inflammatory and Anti-Angiogenic Properties ofFrontiers in pharmacology · 2020Article
- Natural approaches in metabolic syndrome management.Archives of medical science : AMS · 2018Article
- Anti-fibrotic effect of rosmarinic acid on inhibition of pterygium epithelial cells.International journal of ophthalmology · 2018Article
- The Roles of Vitamin C in Skin Health.Nutrients · 2017Review
- Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation.Journal of cancer research and clinical oncology · 2016Article
- High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report.The American journal of case reports · 2016Article
- Vitamin C, a Multi-Tasking Molecule, Finds a Molecular Target in Killing Cancer Cells.Reactive oxygen species (Apex, N.C.) · 2016Article
- Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.Antioxidants & redox signaling · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical doses of ascorbic acid (AA, vitamin C, or its salts) have been reported to exert anticancer activity in vitro and in vivo. One proposed mechanism involves direct cytotoxicity mediated by accumulation of ascorbic acid radicals and hydrogen peroxide in the extracellular environment of tumor cells. However, therapeutic effects have been reported at concentrations insufficient to induce direct tumor cell death. We hypothesized that AA may exert anti-angiogenic effects. To test this, we expanded endothelial progenitor cells (EPCs) from peripheral blood and assessed, whether or not high dose AA would inhibit EPC ability to migrate, change energy metabolism, and tube formation ability. We also evaluated the effects of high dose AA on angiogenic activities of HUVECs (human umbilical vein endothelial cells) and HUAECs (human umbilical arterial endothelial cells). According to our data, concentrations of AA higher than 100 mg/dl suppressed capillary-like tube formation on Matrigel for all cells tested and the effect was more pronounced for progenitor cells in comparison with mature cells. Co-culture of differentiated endothelial cells with progenitor cells showed that there was incorporation of EPCs in vessels formed by HUVECs and HUAECs. Cell migration was assessed using an in vitro wound healing model. The results of these experiments showed an inverse correlation between AA concentrations relative to both cell migration and gap filling capacity. Suppression of NO (nitric oxide) generation appeared to be one of the mechanisms by which AA mediated angiostatic effects. This study supports further investigation into non-cytotoxic antitumor activities of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.